Onco-hematology
RCT | Ruxolitinib achieves greater molecular response and EFS in hydroxycarbamide-resistant Polycythemia Vera
22 May, 2023 | 13:35h | UTCCommentary: Ruxolitinib Appears to Yields Superior Responses in Polycythemia Vera Subtype – Cancer Network
RCT | Superior progression-free survival with Venetoclax-based regimens in first-line CLL treatment
22 May, 2023 | 13:32h | UTCFirst-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: First-Line Venetoclax Combinations vs Chemoimmunotherapy in Fit Patients With CLL – The ASCO Post
Commentary on Twitter
Venetoclax with obinutuzumab or rituximab as first-line treatment for pts with CLL & coexisting conditions has resulted in a large percentage of pts with undetectable minimal residual disease & long progression-free survival.
Read the Research Summary: https://t.co/2i45QN55Hz
— NEJM (@NEJM) May 14, 2023
RCT | The addition of Quizartinib to chemotherapy improves overall survival vs placebo in FLT3-ITD-positive AML patients
18 May, 2023 | 13:40h | UTCQuizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
Acute myeloid leukaemia (AML) is a genetically heterogeneous disease with poor clinical outcomes.
A new study assessed the effect of quizartinib on overall survival in patients with FLT3-ITD-positive newly diagnosed AML, in addition to chemotherapy. https://t.co/MGOoVF5QOa
— The Lancet (@TheLancet) April 27, 2023
Phase 2 RCT | Ropeginterferon shows better results in hematocrit control vs phlebotomy alone in patients withr polycythemia vera
18 May, 2023 | 13:37h | UTCRopeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera – NEJM Evidence
RCT | Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma
16 May, 2023 | 14:48h | UTCNews Release: Investigational drug may improve stem cell transplantation for multiple myeloma patients – Washington University in St. Louis
Commentary on Twitter
A new compound, motixafortide, can safely mobilize an optimal number of stem cells for collection and transplantation in over 90% of 80 patients with multiple myeloma with one injection, reports a phase 3 clinical trial published in @NatureMedicine. https://t.co/23bBzCyoor pic.twitter.com/d9DTs4X1cO
— Nature Portfolio (@NaturePortfolio) April 17, 2023
RCT | Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide for Waldenström’s Macroglobulinemia
16 May, 2023 | 14:24h | UTCBortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström’s Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström’s Macroglobulinemia – Journal of Clinical Oncology (link to abstract – $ for full-text)
Review | Treatment of amyloidosis: present and future
12 May, 2023 | 13:22h | UTCTreatment of amyloidosis: present and future – European Heart Journal Supplements
See all articles in the series here
RCT | Ibrutinib plus rituximab improve CLL PFS vs chemoimmunotherapy, but increased unexplained/cardiac deaths
8 May, 2023 | 13:00h | UTC
Cohort Study | Ibrutinib is associated with increased cardiovascular events and major bleeding in older CLL patients
8 May, 2023 | 12:59h | UTC
Commentary on Twitter
#Ibrutinib was associated with an increased risk of stroke, #AFib and bleeding, especially in older patients. The risk of major bleeding is higher than previously reported. https://t.co/dhP7Kwogdt#JACCCardioOnc #CardioOnc #geriheme #lymsm #leusm #CLL @AkivaDiamond @paolocaimiMD pic.twitter.com/MvzCh1i6LU
— JACC Journals (@JACCJournals) May 4, 2023
4 or more CT scans in childhood correlate with elevated cancer risk
4 May, 2023 | 13:59h | UTCNews Release: Single CT scan in kids low risk for cancers, but 4 or more CTs increases risk – Canadian Medical Association Journal
RCT | Evaluating subcutaneous rituximab for the first-line treatment of low–tumor burden follicular lymphoma
3 May, 2023 | 15:07h | UTCRandomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
RCT | Liso-cel, a CAR T-Cell therapy, significantly improves outcomes in large B-Cell lymphoma second-line treatment
2 May, 2023 | 13:28h | UTCCommentary: Lisocabtagene Maraleucel Bests Standard Care in LBCL – Cancer Therapy Advisor
Single-arm study | Blinatumomab added to chemotherapy in infant lymphoblastic leukemia
28 Apr, 2023 | 13:08h | UTCBlinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia – New England Journal of Medicinev (link to abstract – $ for full-text)
News Release: Immunotherapy strongly improves prognosis of babies with leukemia – Princess Máxima Center
Commentary on Twitter
In this study, the addition of blinatumomab to standard chemotherapy improved disease-free and overall survival among infants with KMT2A-rearranged ALL, with minimal additional toxic effects. https://t.co/fNKOaQQfdN
— NEJM (@NEJM) April 26, 2023
ASCO Guideline Update | Venous thromboembolism prophylaxis and treatment in patients with cancer
25 Apr, 2023 | 14:49h | UTC
Consensus Paper | Management of pathological thoracolumbar vertebral fractures in patients with multiple myeloma
25 Apr, 2023 | 14:11h | UTC
Review | Long-term outcomes following CAR T cell therapy: what we know so far
18 Apr, 2023 | 13:12h | UTCLong-term outcomes following CAR T cell therapy: what we know so far – Nature Reviews Clinical Oncology (if the link is paywalled, try this one in PMC)
Commentary on Twitter
In a new Review now live online, Kathryn Cappell & James Kochenderfer discuss 'Long-term outcomes following CAR T cell therapy: what we know so far' https://t.co/w89HksK1Ay #ImmunoOnc #hemeonc #medonc #leusm #lymsm #MMSM pic.twitter.com/1MEKWvXcKu
— NatureRevClinOncol (@NatRevClinOncol) April 14, 2023
Guideline | First line treatment of newly diagnosed transplant ineligible multiple myeloma
11 Apr, 2023 | 14:22h | UTC
Guidelines on diagnosis and management of chronic neutropenia in adults and children
10 Apr, 2023 | 13:25h | UTC
Commentary on Twitter
Neutropenia diagnosis & management were previously based on physicians' experience or local practices. To harmonize #hematology treatment, #EHA & @eunet_innochron have published a new #EHAGuideline on #neutropenia in adults & children in @Hemasphere_EHA: https://t.co/ifYEtzNlAv pic.twitter.com/CnKuqG03Up
— European Hematology Association (@EHA_Hematology) April 3, 2023
Review | Diagnosis and treatment of chronic lymphocytic leukemia
22 Mar, 2023 | 13:39h | UTCDiagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review – JAMA (free for a limited period)
Audio clinical review: Diagnosis and Management of Chronic Lymphocytic Leukemia – JAMA
RCT | Overall survival with Daratumumab, Lenalidomide, and Dexamethasone in previously treated multiple myeloma
16 Mar, 2023 | 13:07h | UTCOriginal Study: Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma – New England Journal of Medicine
Primary myelofibrosis | 2023 update on diagnosis, risk-stratification, and management
16 Mar, 2023 | 12:57h | UTC
Retrospective Cohort | Arrhythmogenic cardiotoxicity associated with contemporary treatments of lymphoproliferative disorders
14 Mar, 2023 | 13:27h | UTC
DNA sequencing may identify an increased risk of relapse in adults with AML prior to hematopoietic cell transplantation
13 Mar, 2023 | 14:47h | UTCDNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant – JAMA (free for a limited period)
Commentary on Twitter
Among patients w AML in first remission prior to allogeneic hematopoietic cell transplant, the persistence of residual variants in the blood at an allele fraction ≥0.01% was assoc'd w increased relapse & worse survival vs those w/o these variants. https://t.co/KCnaQ1NRXJ
— JAMA (@JAMA_current) March 11, 2023
Cohort Study | Personalized progression prediction in patients with MGUS or smouldering multiple myeloma
9 Mar, 2023 | 13:59h | UTCInvited Commentary: The PANGEA model: catching the drift from precursor conditions to myeloma in individual patients – The Lancet Haematology
Commentary from the author on Twitter (thread – click for more)
‼️ The PANGEA Model is out now @TheLancetHaem ‼️
A 🧵on how PANGEA improves prediction accuracy of MGUS & SMM progression to #MultipleMyeloma & is the 1st model that is #personalized to the individual #mmsm patient! @LabGhobrial @DanaFarber | 1/https://t.co/e2rEWXLahT
— Annie (@anniencowan) February 28, 2023
RCT | Momelotinib vs. danazol in symptomatic patients with anemia and myelofibrosis
1 Mar, 2023 | 13:39h | UTCMomelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study – The Lancet (link to abstract – $ for full-text)